KMT2A and breast carcinoma: Mechanistic investigations indicated that the ROR could enhance the tissue inhibitors of metalloproteinase 3 (TIMP3) transcription through demethylating the TIMP3 promoter by binding to Mixed-lineage leukemia 1 (MLL1), thus accelerating breast cancer progression [36].